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Background: Tailored psychological interventions based on individual risk factors
are likely to improve treatment for Alcohol Use Disorders (AUDs). Key risk factors
for poor treatment outcome include alcohol craving, positive expectations of alcohol
consumption, and impulsivity.
Design: Pragmatic randomized Cognitive-Behavioral Treatment (CBT) trial.
Setting: Public hospital alcohol and drug clinic.
Participants: Three-hundred seventy-nine patients (65% male; Ageyears M = 44.32,
SD = 10.75) seeking treatment for AUD.
Procedure: Patients were randomly allocated into treatment as usual (TAU) or targeted
treatment. Patients in targeted treatment were allocated one of three treatment modules
focusing on craving, positive expectancy, or impulsivity based on assessment results.
Treatment included eight, 1 h sessions of CBT over 12 weeks delivered by clinical
psychologists.
Hypotheses: Targeted treatment was expected to have fewer drinking days and
consume less alcohol during the treatment period than TAU. Improvement in targeted
mechanisms was predicted to be greatest for patients within matched conditions.
Results: Patients attended an average of 4.4 sessions with 93 (25%) completing
the whole 12-week treatment episode. The mean proportion of drinking days between
sessions was 5% with an average consumption of 64 grams of ethanol. No significant
effect of targeted treatment was identified on drinking days or consumption. The craving
(b=−18.97, 95% CI=−31.44,−6.51) and impulsivity (b=−26.65, 95% CI=−42.09,
−11.22) modules demonstrated significant reductions in their targeted constructs over
treatment, above TAU. Only reduction in craving was associated with reduced drinking
days [exp(b) = 0.958, p = 0.003] and alcohol consumption [exp(b) = 0.962, p = 0.02].
Significant indirect effects for the targeted cravingmodule through craving reduction were
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identified for reduction in drinking days (β = −0.72, 95% CI = −1.50, −0.158) and
alcohol consumption (β = −0.78, 95% CI = −1.72, −0.11).
Conclusions: In the context of a public health service, the effectiveness of individualized
treatment targeting risk mechanisms identified during pre-treatment assessment was
not confirmed. Some evidence was found for improved treatment response to the
implementation of a manualized craving module when pre-treatment craving was high.
Keywords: alcohol dependence, impulsivity, craving, expectancies, CBT, personalized, RCT
INTRODUCTION
Improvements in treatment outcomes for Alcohol Use Disorders
(AUDs) have been modest despite substantial research (1).
Alcohol is among the leading contributors to the global burden
of morbidity and disease, with the majority of this burden
attributable to AUDs (2–4). Evidence-based interventions for
AUD are available, though relapse rates are high (1, 5, 6).
About one in five patients remain abstinent 12 months post-
treatment (7). Comprehensive reviews of AUD treatment and
rehabilitative services conclude that individual differences are
likely to determine differential treatment response (5, 8).
Efforts at personalizing psychological AUD treatments have
focused on matching patients to treatments. Two large scale
studies have been conducted examining differential treatment
effects with a priori hypotheses of treatment response based
on individual characteristics (9, 10). The largest, Project
MATCH, recruited 1,726 patients across nine treatment sites. It
tested 20 hypothesis regarding interactions between 10 patient
characteristics in three manualized treatments—Cognitive-
Behavioral Therapy (CBT), Motivational Enhancement Therapy
(MET), and Twelve Step Facilitation (9). More recently, the
United Kingdom Alcohol Treatment Trial (UKATT) study
recruited 742 patients, across two treatment conditions—
MET and social and behavior network therapy (11). Five
matching hypothesis were proposed some of which were drawn
from post-hoc findings of Project MATCH. In both studies,
patients were randomly allocated to a condition and a priori
(characteristics) hypotheses were retrospectively examined on
treatment completion. Treatment matching was not found to
improve outcomes in either study (9, 12, 13). Authors concluded
that “. . . the intuitively appealing notion that treatment matching
can appreciably enhance treatment effectiveness has been
severely challenged” (14, p. 1690).
As an alternative to matching patients to different treatments
based on individual characteristics, the UKATT Research Team
emphasize the scope for prospectively tailoring treatments to
patients. Eclectic psychotherapy approaches involving personally
tailoring therapy are widely applied in the treatment of
mental health disorders (15). Case conceptualization and
treatment planning are central to psychological interventions
but little progress has been made to standardize and assess
individually tailored approaches. This is partly due to an
absence of replicable research identifying patient characteristics
with prognostic value (16). Furthermore, such mechanisms
need to be modifiable to be treatment targets. Litten et al.
recommend a framework by which target mechanisms can be
derived for personalized interventions. They propose alcohol
addiction comprises 3-stages: binge-intoxication, withdrawal–
negative affect, and preoccupation–anticipation (“craving”) (17).
These stages reflect movement of drinking motivated by
impulsivity and positive-reinforcement expectations to drinking
for relief. This process maps well onto three prominent
constructs within psychosocial conceptualizations of AUD:
impulsivity (18, 19) alcohol outcome expectancies (20–22),
and craving (23). Identifying individual differences in patient
profiles comprising these constructs has potential for informing
personalized interventions.
Craving is common across Substance Use Disorders (SUDs)
with implications in diagnosis, prognosis, and treatment (23–
25). Ninety-nine percent of substance abuse treatment agencies
surveyed in the U.S. reported that it is useful to consider craving
in treatment planning (26). Craving is a major risk factor for
relapse, often comprising physiological discomfort, intrusive
substance-related cognitions, and affective distress (27, 28). Each
of these experiences are recognized targets of cognitive and
behavioral interventions (29–31). There is a high level of variance
in craving severity among patients presenting for treatment
of AUD (25), making it a prime candidate for individualized
treatment approaches.
Expectations of the outcome of alcohol consumption are
central to cognitive and behavioral theories of addiction (20, 21,
32). Positively biased alcohol outcome-expectancies (AOEs) are
predictive of drinking initiation, progression to problematic use,
and maintenance of AUDs (20, 21). Reduction of positive AOEs
is proposed as an important aspect of successful treatment (22,
29, 32, 33) and is commonly targeted within AUD interventions
(29, 34, 35). Reduction in positive AOEs is proposed to reduce
motivation to drink and enhance drinking refusal self-efficacy
(22, 32, 33).
Impulsivity is broadly considered a predisposition for action
with insufficient forethought and impaired behavioral restraint
(36). Impulsivity is causally linked to heavier alcohol use
(37) and predictive of the development of alcohol misuse
(38, 39). It is related to poorer SUD treatment outcomes
(18, 40–42) and associated with enhanced relapse risk 12-
months post-treatment (43, 44). As impulsivity is widely
considered a stable trait, the goal of intervention is to improve
management and expression of impulsivity (45). Limited research
has examined the effectiveness of targeting impulsivity within
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AUD interventions, although it is recognized as an important
avenue for investigation (18, 42, 46).
Identification of individual differences in modifiable
mechanisms contributing to the maintenance of AUDs may
facilitate individually tailored psychological interventions. Such
interventions are expected to improve treatment efficiency
and outcome. This study randomly allocated patients seeking
treatment for AUD into treatment as usual (TAU) or targeted
treatment in a public hospital clinic. Patients in the targeted
treatment group were allocated one of three treatmentmodules—
craving, positive expectancy, or impulsivity–depending on
pre-treatment assessment results. The targeted treatment
condition was expected to have significantly greater retention,
fewer lapses during treatment, and less severe lapses than
treatment as usual (TAU). Improvements in the mechanisms of
interest (craving, AOEs, and impulsivity) were predicted to be
greatest for patients within the individually targeted condition.
METHOD
The study was a single blind pragmatic randomized control
trial with a CBT intervention. Consecutive alcohol dependent
patients (subsequently referred to as AUD, consistent with DSM-
5 nomenclature) attending a metropolitan hospital outpatient
drug and alcohol service were randomly allocated to TAU or
targeted treatment. Treatment was administered by registered
clinical psychologists (masters level or above). Human research
ethics approval was obtained and the trial was registered at
the Australian New Zealand Clinical Trials Registry (Trial ID:
ACTRN12613000865718).
Participants
Participants were 379 patients treated consecutively from January
2014 to January 2017. Sample characteristics are presented in
Table 1. Inclusion in the trial required that patients be at least
18 years old, meet DSM IV-TR criteria for alcohol dependence
and be seeking abstinence as the primary treatment goal (not
controlled drinking). Patients were excluded from the study if
they had a comorbid substance dependence (with the exception
of nicotine), were taking Disulfiram or any prescribed opioid, or
if they could not provide written, informed consent.
Measures
The Severity of Alcohol Dependence Questionnaire
(SADQ)
The SADQ is a 20-item self-report measure assessing physical
withdrawal, affective withdrawal, drinking to relieve withdrawal
symptoms, alcohol consumption, and rapidity of reinstatement
of alcohol dependence (47). Higher scores are indicative of
greater alcohol dependence severity. The SADQ has good test-
retest reliability and concurrent validity (47). Internal consistency
of the SADQ within the current study was good (Cronbach’s α=
0.93, 95% CI= 0.92–0.94).
The Alcohol Use Disorders Identification Test (AUDIT)
The AUDIT interview version was administered by experienced
nursing staff at patient intake. The AUDIT comprises 10-items
assessing recent alcohol use, symptoms of alcohol dependence,
and alcohol related problems. Higher scores suggest greater
risk of harmful drinking and likelihood of AUD. Good internal
consistency, as well as sensitivity and specificity in the detection
of AUDs has been demonstrated (48). Internal consistency of the
AUDIT was good within the current study (Cronbach’s α = 0.87,
95% CI= 0.85–0.89).
The Alcohol Craving Experience
Questionnaire—Frequency (ACE-F)
The ACE-F is an 11-item scale assessing desire related
cognitions over the previous week. Participants respond via
an 11-point visual analog scale with anchors 0 (not at all)
and 10 (constantly/extremely). The ACE-F has demonstrated
good construct validity, predictive validity, concurrent validity,
discriminant validity, internal reliability, and test-retest reliability
(25, 49, 50). Internal consistency of the ACE within the current
study was excellent (Cronbach’s α= 0.95, 95% CI= 0.94–0.96).
Drinking Expectancy Questionnaire (DEQ)
The DEQ is a 43-item self-report measure assessing positive
and negative AOEs. Response options range from one “Strongly
Disagree” to five “Strongly Agree” on a 5 point Likert scale.
The DEQ comprises six subscales: Assertion (10-items) assesses
positive beliefs regarding social confidence and assertiveness;
Sexual Enhancement (5-items) refers to expectations of enhanced
feelings of attractiveness and sexual interest; Cognitive Change
(4-items) assesses beliefs of improved thought generation and
clarity; Tension Reduction (4-items) evaluates beliefs about
the relaxing effects of alcohol; Affective Change (12-items)
measures beliefs regarding the effects of alcohol on negative
mood states, such as sadness, irritability, and aggressiveness;
and Dependence (8-items) reflects beliefs regarding a personal
sense of addiction and perceived loss of control when drinking.
The Assertion, Sexual Enhancement, Cognitive Change, and
Tension Reduction sub-scales are positive AOEs, as they represent
positive expectations of alcohol, while the Affective Change scale
is a negative AOE. As the Dependence scale assesses beliefs
beyond the acute effects of alcohol, it is considered to be a
broader construct than the other scales (51). The DEQ has
sound internal consistency and test-re-test reliability, and good
construct, convergent, and predictive validity (52). The positive
sub-scales of the DEQ were combined to form a proxy for total
“positive expectancies.” Combination of all positive expectancy
items demonstrated acceptable internal consistency (Cronbach’s
α= 0.78, 95% CI= 0.75–0.81).
Dickman’s Impulsivity Inventory—Dysfunctional
Impulsivity Scale (DIS)
The DIS is a sub-scale of Dickman’s Impulsivity Inventory,
assessing the tendency to act with a lack of forethought when this
tendency is a source of difficulty; (53). The DIS comprises 12-
items with dichotomous (True/False) response options. The DIS
has demonstrated good internal reliability, construct validity, and
excellent concurrent validity with other established impulsivity
scales (53, 54). The DIS demonstrated good internal consistency
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TABLE 1 | Descriptive statistics of the sample at pre-treatment assessment (n = 379)a.
Targeted treatment module
TAU Targeted treatment Impulsivity Expectancy Craving Total
n = 193 n = 186 n = 45 n = 64 n = 77 n = 379
Mean (SD)
ALCOHOL USE MEASURES
AUDIT 28.22 (8.92) 27.79 (8.28) 26.80 (8.22) 27.68 (8.29) 28.47 (8.34) 28.01 (8.60)
SADQ 22.06 (13.33) 23.16 (11.99) 23.53 (11.59) 21.66 (11.98) 24.19 (12.26) 22.6 (12.68)
TARGETED ASSESSMENTS
DEQ-positive 75.97 (10.94) 77.61 (10.10) 74.11 (9.85) 83.17 (10.54) 75.04 (7.74) 76.78 (10.55)
ACE-F 43.27 (29.21) 46.36 (28.69) 40.89 (24.22) 27.03 (23.55) 65.01 (23.16) 44.66 (29.01)
DIS 3.94 (3.28) 5.17 (3.56) 8.71 (2.74) 3.55 (3.12) 3.84 (2.93) 4.42 (3.49)
Age, years 45.26 (10.36) 43.34 (11.09) 41.32 (10.54) 44.72 (12.01) 43.38 (10.56) 44.32 (10.75)
Sessions attended 4.34 (2.71) 4.47 (2.70) 4.49 (2.75) 4.73 (2.73) 4.23 (2.67) 4.4 (2.7)
n (%)
Gender, male 128 (66%) 118 (63%) 26 (58%) 39 (61%) 53 (69%) 246 (65%)
Supplementary pharmacotherapyb 63 (33%) 65 (35%) 17 (38%) 23 (36%) 25 (32%) 128 (34%)
aContinuous data presented as Mean (Standard Deviation).
bTaken acamprosate, naltrexone, or both during treatment.
within the current study (Cronbach’s α = 0.84, 95% CI = 0.81–
0.86).
Drinking Behavior
Patient were asked to recall days of alcohol consumption since the
previous treatment session and estimate the quantity consumed
on each drinking occasion, guided by the time-line follow-back
procedure (55). Drinking days was standardized by dividing the
total abstinent days by the number of days the patient was in
treatment.
Procedure
Patients were referred to the alcohol and drug service following
inpatient hospital admission, or by their General Practitioner or
self-referral. Intake was conducted by a nurse or social worker,
who determined eligibility for the AUD treatment program.
This included obtaining patient consent and completion of
the pre-treatment assessments. No incentive was offered to
patients enrolled in the trial. Patients were advised to remain
abstinent and scheduled to begin treatment within 7-days.
Randomization to treatment condition (TAU or Targeted) was
based on a random number sequence generated by program
“Research Randomizer” version 4.0 (56). Randomization order
was concealed from enrolling and treating staff by a research
assistant, who revealed treatment condition upon completion
of pre-treatment assessments. Treatment comprised eight face-
to-face, one-on-one, sessions of CBT over 12-weeks. Targeted
treatment involved administration of one of three manualized
modules targeting craving, AOEs, or impulsivity over four of
the eight sessions. Module selection was based on highest
standardized pre-treatment score on the ACE-F, DEQ, or DIS
respectively. Scores were standardized relative to AUD norms
to enable comparison across scales. Targeted treatment modules
were adapted from existing treatment manuals of evidence-
based cognitive-behavioral therapies by registered clinical
psychologists with extensive experience treating AUDs. Treating
psychologists were trained inmodule administration. Assessment
reports of the targeted treatment scales were provided to
psychologists if their patients were allocated to the targeted
condition. Psychologists recorded drinking behavior and adjunct
pharmacotherapy (naltrexone, acamprosate, or both) at each
session. The assessment battery was readministered at 12-weeks.
It must be emphasized that this was a pragmatic trial, intended
to examine effectiveness of targeted treatment within a “real-
world” setting, enhancing external validity (57). Psychologists
adhered as closely to the targeted treatment modules as possible,
though were free to diverge according to their clinical judgment,
such as addressing high risk situations. Psychologists recorded
how closely they adhered to the treatment manual (0 = no
fidelity to 10= complete fidelity) for patients enrolled in targeted
treatment.
Intervention Summary
TAU was CBT, where common treatment elements include
motivational interviewing, psychoeducation, identification of
risks for relapse, problem-solving skills training, relaxation
strategies, and relapse prevention planning (29, 58–60). The
craving module comprised: craving education, self-monitoring
of craving and urges, short-term behavioral strategies for
coping with craving, and cognitive strategies for craving
management (58, 61). The expectancy module aimed to educate
patients about how learned alcohol outcome expectancies
contribute toward development and maintenance of drinking
problems (32), facilitate development of behavioral alternatives
to positive expectancies (e.g., relaxation training, social-skills
training), and challenge positively-biased expectancies through
cognitive strategies (29). The Impulsivity module was process
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oriented, intending to help patients recognize the benefits
of planning and considered deliberation. This was achieved
through the use of clear session structure and documentation
to encourage reflection. Specific components of the module
included education about impulsivity, cognitive and behavioral
response-inhibition strategies (62), structured problem solving
(63), and identification of alternative rewards. Module manuals
are available upon request.
Statistical Analysis
Data analysis were conducted in R version 3.3.3. Assessment
scores were standardized by percentage of maximum possible
score (POMP) to facilitate interpretation and comparison across
scales (64). Assumptions of normality and linearity were assessed
via inspection of residual and diagnostic plots.
Power analysis
A previous study at this treatment site, using an identical
generic CBT treatment program (TAU Condition) demonstrated
medium effect sizes to detect treatment group differences (65).
Accepting an effect size of 0.3 (w), a = 0.05 and power of 0.90,
a minimum of 117 subjects was required for a between group
contrast (Critical Chi= 3.84).
Treatment effects
The primary outcome of interest was drinking behavior over
treatment. Drinking behavior was operationalized as two
outcomes, the proportion of drinking days and quantity of
alcohol consumed between sessions. Separate analyses were
conducted for each drinking behavior. Inspection of the
proportion of drinking days and consumption variables revealed
zero-inflated heavy tailed positively skewed distributions.
Tweedie Compound Poisson models were utilized as they are
appropriate for analysis of non-negative continuous data with
inflation in discrete zeros (66–68). Data were hierarchically
structured, with drinking behavior between sessions nested
within patients. Compound Poisson generalized linear mixed
models (CPGLMM), treating “patient” as a random effect with
“session number” (1–8) nested within, enabled assessment of
within and between patient differences in drinking behaviors
(intercepts) as well as within and between patient changes in
drinking behavior over treatment (slopes). All models were fit
using Laplace approximated maximum likelihood estimation in
R (version 3.3.3) package “cplm” (66).
All available data were included in the models. Baseline
models included a random intercept and “session number.”
Covariates: age, gender, severity of alcohol dependence, and
medication use (acamprosate, naltrexone, or both) were included
sequentially as fixed effects, and retained if they significantly
improved model fit as assessed by likelihood ratio tests (69).
Pattern-mixture modeling was used to identify and model
potential differences in outcomes between patients who dropped
out and those who completed treatment by including patient
completion (No or Yes) as a fixed effect (70, 71). Moderating
effects of each predictor on the trajectory of drinking behavior
were assessed by adding the interaction between each predictor
and session number to the model. Upon completion of the
“covariates model,” pre-treatment targeted assessment scores
(DEQ-Positive, ACE-F, DIS) and corresponding assessment by
session number interactions were included to control for bias in
module allocation pertaining to inflation in these constructs. This
formed the “control model.”
Effects of treatment condition were examined by including
condition (TAU or Targeted Treatment) as a fixed effect within
the control model. Effects of condition on the trajectories of
drinking behavior were assessed by including interaction between
treatment condition and session number in the model. In a
separate model, differential effects among the targeted treatment
modules were examined by including a nominal module variable
(TAU, Impulsivity, Expectancy, or Craving) to the control model
and a session number x module interaction term in the following
step. Statistical significance of fixed effects within the final
models was estimated by Type III Wald tests in order to
partition variance of effects simultaneously comprising part of an
interaction.
Treatment mechanisms
Mediation of the effect of treatment module on drinking
behaviors by reduction in the targeted constructs (pre to post-
treatment) was tested using the joint significance procedure
(72). Support for mediation would be drawn from a significant
association between treatment module assignment and reduction
in the targeted construct (path a), and a significant association
between reduction in the targeted construct and drinking
behavior (path b). Separate mediation models were tested for
each treatment module and each drinking behavior, resulting in
six mediation analyses.
Path a was assessed by separate linear mixed models (LMM)
using R package “lme4” (73). Cases without post-treatment
targeted assessments were excluded from the analyses (complete
cases, n = 93). The outcomes were targeted assessment (craving
= ACE-F; impulsivity = DIS; positive expectancy = DEQ)
nested within assessment occasion (0= pre-treatment, 1= post-
treatment). “Patient” was modeled as a random effect. Models
included a random intercept, assessment occasion (slope),
covariates (age, sex, and pre-treatment severity of dependence
score), treatment module, and a “treatment module” × “pre-
treatment targeted assessment” interaction term. The effect of
interest (path a) was represented by the interaction between
“assessment occasion: post-treatment” and “treatment module.”
An additional interaction term comprising pre-treatment ACE-
F score and medication-use was included in the craving model
to control for potential differences in conjoint pharmacotherapy
as a function of pre-treatment craving severity. Models were
fit using Maximum Likelihood estimation. Significance was
approximated by Wald based 95% confidence intervals around
fixed effects. Random slopes were not assessed.
Path b was assessed by separate CPGLMMs on the
complete cases. Covariate models were constructed using
identical procedures to the Treatment Effects analyses. All
“pre-treatment targeted assessment scores” and “pre-treatment
targeted assessment × session number” interaction terms were
held constant in all models. “Post-treatment targeted assessment”
was included in the final step. As “pre-treatment targeted
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assessment” scores were held constant within the models, the
“post-treatment targeted assessment score” provided a proxy for
residualized change in the targeted assessment (path b). As the
temporal sequence of the predictor in path b (change in target
mechanism) is measured after the outcome (drinking behaviors),
it is not possible to infer a causal relationship between reduction
in target mechanisms and reduction in drinking behavior. In fact,
the relationship between mechanism reduction and reduction in
drinking is expected to be bidirectional. However, differences
between the targeted modules and TAU observed in these
pathways will provide insight into the hypothesized mechanisms
of action.
Standardized indirect effects were estimated using R package
“Rmediation” (74). Confidence intervals were estimated by the
product of confidence limits for indirect effects (PRODCLIN)
procedure (75). Complete Treatment Effects models were
constructed on the complete cases to assess consistency of results.
Disclosure of divergence to planned analyses
The present analysis method deviates from that proposed
in the 2013 trial registration. Advanced statistical methods
better suited to modeling this data became accessible through
developments in statistical software [e.g., (62)]. In contrast
to the planned analyses these developments enabled modeling
of patient attrition, distributional properties of the outcomes,
covariates, and differences in growth of drinking behavior over
treatment. In doing so, error variance was minimized and
statistical power maximized (76).
RESULTS
Descriptive Statistics
Three-hundred and ninety-seven patients consented to the trial
and completed pre-treatment assessments. Ninety-seven percent
(n = 367) scored =>6 on the AUDIT, indicating a likely AUD
(77, 78). Thirty-three percent (n = 128) scored <=15 on the
SADQ, indicatingmild dependence; 40% (n= 153) scored=> 16
and <= 30 indicating moderate dependence; and 26% (n = 98)
scored=>31, indicating severe dependence. Three-hundred and
thirty-eight patients (11%) attended at least one session, with 93
(25%) re-assessed at 3 months. No significant differences in the
proportion of patients who completed treatment were observed
between TAU and Targeted Treatment groups [χ2
(1)
= 0.4,
p = 0.53] or treatment modules [Impulsivity χ2
(1)
= 0.57,
p = 0.45; Expectancy χ2
(1)
= 0.6, p = 0.44; Craving χ2
(1)
= 0.004,
p = 0.95]. The mean sessions attended was 4.4 (SD = 2.70). No
significant differences in the number of sessions attended were
observed between TAU and Targeted Treatment (U = 17970.00,
p = 0.616) or treatment modules [χ2
(3)
= 1.26, p = 0.738]. A
CONSORT flow chart of patient recruitment and retention is
provided in Figure 1, as per Boutron et al. . The mean proportion
of drinking days between sessions was 5% (SD = 14.71) and
mean consumption was 64 (SD = 309.41) grams of ethanol.
Post-treatment fidelity ratings were available from 50 patients.
Mean fidelity rating for the targeted treatment condition was
6.26 (SD = 2.39) out of 10. One-way analysis of variance was
not indicative of significant differences in fidelity among the
treatment modules [F(2, 47) = 0.84, p= 0.453].
Part 1: Main Effects of Condition
Separate CPGLMM control models were constructed for
the outcomes “proportion of drinking days” and “quantity
of consumption.” Superiority of targeted treatment to TAU
was assessed by adding treatment condition (TAU, Targeted
Treatment) to each control model. Differential effects among
targeted modules were similarly examined by adding module
(TAU, Impulsivity, Expectancy, Craving) to each control model.
Results of these four models are summarized in Table 2.
Proportion of Drinking Days
After controlling for covariates and baseline targeted
assessments, neither drinking behavior significantly changed
over the course of treatment. Each year increase in age was
associated with a 1% reduction in the proportion of drinking
days per session attended. Each unit increase in POMP DIS
score was associated with a 0.03% increase in proportion of
drinking days per session. Being male was associated with a 51%
lower proportion of drinking days over treatment. Each unit
increase in the ACE-F was associated with 2% increase in total
proportion of drinking days. No significant effects of dependence
severity, age, pharmacotherapy, or completion status on model
intercepts or slopes were identified. No significant effect of
treatment condition or treatment module was identified on the
intercept or trajectory of the number of drinking days during
treatment.
Consumption
Progression of sessions attended was not independently
associated with an increase in alcohol consumption, but was
moderated by POMP ACE-F score with each unit increase
associated with a 0.04% reduction in consumption per session
attended. Independent of session, each unit increase in POMP
ACE-F score was associated with a 2% increase in total alcohol
consumption. A unit increase in POMP DEQ-Positive was
associated with a 5% overall reduction in consumption over
the course of treatment. Being male was associated with 48%
less alcohol consumption over treatment (p = 0.007). Each
year increase in age was associated with a 3% reduction in
alcohol consumption during treatment. No significant effects
of dependence severity, pharmacotherapy, or completion status
on model intercepts or slopes were identified. Treatment
condition and module were not significantly related to overall
consumption over treatment or progression of consumption
over treatment.
Part 2: Mechanisms of Change
Path a
LMMs holding covariates and baseline ACE-F score, indicated
the craving module was predictive of a 18.97 (SE = 6.36, 95%
CI=−31.44,−6.51) point reduction in ACE-F score (Figure 2).
This effect occurred above a significant main effect of TAU
(b = −16.52, SE = 4.27, 95% CI = −24.89, −8.14). The
impulsivity module was predictive of a 26.65 (SE = 7.87, 95%
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FIGURE 1 | CONSORT flow diagram of patient trial recruitment and retention modified for individual randomized controlled trials of nonpharmacologic treatments (79).
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FIGURE 2 | Path figure of the effect of the craving treatment module on drinking behaviors as mediated by change in craving. Craving was standardized as
percentage of maximum possible ACE-F score (0–100). Each unit reduction in craving is associated with a reduction in drinking behavior by the product of 1×exp(b).
*p < 0.05, **p < 0.01.
CI = −42.09, −11.22) reduction in DIS score post-treatment,
above the non-significant effect of TAU (b = −4.51, SE = 3.75,
95% CI = −11.86, 2.83). The Expectancy treatment module
was not significantly predictive of post-treatment Positive DEQ
score (b = −1.45, SE = 2.66, 95% CI = −8.08, 4.02), above
the significant effect of TAU (b = −7.74, SE = 1.47, 95%
CI=−10.62,−4.86).
Path b
Reconstructed CPGLMM models on the complete cases were
consistent with the full dataset, where treatment condition
was not significantly predictive of proportion of drinking
days or quantity of alcohol consumption over treatment.
Adding post-treatment ACE-F score to the covariates
models significantly improved fit with both drinking days
[exp(b) = 1.04, p = 0.003] and quantity of alcohol consumption
as outcomes [exp(b) = 1.04, p = 0.020]. Each unit increase
in residualized post-treatment POMP ACE-F was associated
with a 4% increase in the proportion of drinking days and
3.8% increase in alcohol consumption. Residualized post-
treatment ACE-F was not found to affect growth in drinking
days [exp(b) = 1.00, p = 0.353] or alcohol consumption
[exp(b) = 1.00, p = 0.243] over treatment. Post-treatment
POMP DIS and DEQ-Positive scores were not significantly
related to the intercepts or slopes of either drinking behavior
over treatment. As the craving module predicted significant
reductions in craving score above TAU (path a) and reductions
in craving significantly predicted less alcohol consumption
and less drinking days over treatment, the joint significance
procedure indicates there is evidence for mediation. This
was further supported by significant standardized indirect
effects of the craving module on alcohol consumption
(β = −0.78, SE = 0.415, 95% CI = −1.72, −0.11) and
drinking days (β = −0.72, SE = 0.347, 95% CI = −1.50,
−0.158).
DISCUSSION
The study compared the effectiveness of standard CBT for
AUD to a tailored CBT treatment program based on the
psychometric profiles of three mechanisms—craving, positive
expectancy, and impulsivity–in a public health clinic. Contrary
to hypotheses, no significant effect of targeted treatment on
patient retention, proportion of drinking days over treatment, or
quantity of alcohol consumption over treatment was identified.
Nor were differences observed in the trajectory of drinking
behaviors over treatment. Indirect support may be drawn for
the craving treatment module. Patients within the craving
module demonstrated reductions in craving more than twice
those within TAU, and reduction in craving was associated
with reduced alcohol consumption and fewer drinking days
over treatment. This resulted in a significant indirect effect
of the craving module, predicting a 0.78 SD reduction in
alcohol consumption and 0.72 SD reduction in drinking days
relative to TAU. This provides some evidence for improved
treatment response to the implementation of a manualized
craving module when pre-treatment craving is high. However,
no evidence was found to support the prediction that targeting
positive expectancies or impulsivity based on pre-treatment
assessments would be superior to TAU in reducing drinking over
treatment.
The impulsivity module, and no other module, significantly
reduced reported dysfunctional impulsivity among treatment
completing patients. This finding should be interpreted carefully,
as impulsivity is widely considered an enduring trait (18). We
do not interpret this finding as suggesting that the patients are
inherently less impulsive, but rather that the impulsivity module
improved patients’ ability to manage dysfunctional impulses.
Surprisingly, this reduction was not significantly related to
reduced drinking behavior over treatment. This may indicate
that impulsivity may not be as important to effective treatment
response as initially thought. An alternative explanation may be
that the relative risk of lapse as predicted by the standardized
assessments is not equivalent across measures, as is assumed
by the module allocation procedure. Future module assignment
may be improved by weighting standard scores relative to
established effect sizes for the targeted assessments. Follow up is
required to identify whether reduction in reported dysfunctional
impulsivity is sustained over time and if it improves long-term
outcomes.
The expectancy module did not significantly reduce positive
expectancies above TAU. This may suggest that the positive
expectancy module did not offer sufficient unique influence
over the intended construct. It may be that TAU addresses
positive expectancies sufficiently as it stands, or that the effect of
the present intervention was too small to detect. Furthermore,
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reduction in positive expectancy was not significantly associated
with reduction in drinking behavior over treatment.
Caution is recommended when interpreting any non-
hypothesized effects identified among the covariates within the
analyses. As the large number of tests make the likelihood
of a false-positive finding among the covariates high, any
non-hypothesized effects of interest require careful theoretical
consideration subsequent replication.
Conducting a pragmatic trial within a public drug and alcohol
outpatient hospital facility was ideal for determining intervention
effectiveness in a “real world” setting. However, restrictions of
public hospital and ethical protocols limit levels of experimental
control. Among the primary limitations were the absence of
independent fidelity testing and restrictions in assessment. More
frequent assessment of the target construct is required to
determine the direction of effect between targeted mechanism
change and drinking behavior. There were also restrictions in
experimental design as treatment of patients within the targeted
treatment module was dictated by pre-treatment assessment
results not random allocation. This was to minimize the risk of
compromising the treatment efficacy of the targeted treatment
modules. For example, a patient who scores very high on craving
and very low on impulsivity, but is allocated to the impulsivity
module, is unlikely to respond well to treatment. This also
increases the likelihood of low treatment fidelity by the treating
psychologists. Conclusions drawn from this study are also limited
to initial treatment response. Long-term follow ups are not
compulsory for patients, many opt not to return, and the data
that is available is subject to selection bias.
The ability to appropriately tailor psychotherapy to individual
patient characteristics has long been recognized as crucial
to the progression of treatment efficacy (15). Standardized
methods of treatment matching, and in this study, tailoring
treatment, have yet to demonstrate utility in the treatment of
AUD (13, 80). This study provides evidence for implementing
standardized craving modules for patients with high craving
pre-treatment. More nuanced understanding of mechanisms
of risk, change, and moderators of treatment response are
required to enhance standardized approaches to tailoring
psychotherapy.
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